About Sandostatin LAR® Depot

Indications and Usage

Acromegaly

Sandostatin LAR® Depot (octreotide acetate for injectable suspension) is indicated for long-term maintenance therapy in acromegalic patients for whom medical treatment is appropriate and who have been shown to respond to and can tolerate immediate release Sandostatin® (octreotide acetate) Injection. The goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal. Sandostatin LAR® Depot can be used in patients who have had an inadequate response to surgery or in those for whom surgical resection is not an option. It may also be used in patients who have received radiation and have had an inadequate therapeutic response.

Carcinoid Tumors and VIPomas

Sandostatin LAR® Depot is also indicated for long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and for the long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors in patients in whom initial treatment with immediate release Sandostatin® Injection has been shown to be effective and tolerated (1).

The controlled clinical trials that support the marketing clearance of Sandostatin LAR® Depot for acromegaly and carcinoid syndrome did not include determination of effect on tumor size or rate of growth. Sandostatin LAR® Depot is not indicated for tumor shrinkage (1).